Back to top

Image: Bigstock

Is PG Worth Buying as Growth Improves but Its Valuation Stays Rich?

Read MoreHide Full Article

Key Takeaways

  • PG's organic sales rose 4%, driven by volume gains and broad-based growth across categories and regions.
  • PG's premium valuation and rising input costs pose risks, despite improving sales momentum.
  • Strong cash flow supports dividends and buybacks, but modest earnings growth limits PG's near-term upside.

The Procter & Gamble Company (PG - Free Report) is showing better operating momentum, but the investment case remains balanced. Fiscal first-quarter organic sales growth accelerated, volumes improved and cash generation stayed healthy.

The trade-off is valuation. PG commands a premium to its sub-industry, sector and the S&P 500 while fiscal 2027 earnings growth guidance remains modest and cost pressures are building.

PG's Growth Case Is Improving

Fiscal first-quarter 2027 organic sales increased 4%, above management’s full-year organic sales growth guidance of 1-3%. Volume rose 2.4%, favorable mix added 1.1% and pricing contributed 0.4%, showing that growth was driven by more than price increases.

The breadth was encouraging, with all 10 product categories and six geographic regions posting organic growth. For context, Colgate-Palmolive Company (CL - Free Report) reported 3.6% organic sales growth in its third quarter of 2026, while Kimberly-Clark Corporation (KMB - Free Report) reported a 1.3% organic sales decline in its third quarter. PG’s result therefore compares favorably with recent growth trends at two major consumer-products peers.

PG's Premium Valuation Raises the Bar

PG trades at 23.81X forward 12-month earnings, above 21.05X for the Zacks sub-industry, 18.09X for the Zacks Consumer Staples sector and 18.05X for the S&P 500. The stock also trades above its five-year median of 23.26X.

Zacks Investment Research
Image Source: Zacks Investment Research

That premium leaves less room for operating disappointment. Shares have gained 17.4% in the past three months, while the Zacks sub-industry declined 0.3%, so continued upside may require sustained volume growth, stable market share and stronger earnings conversion.

PG's Cost Headwinds Limit Upside

Core gross margin contracted 150 basis points in the fiscal first quarter. Commodity costs created a 140-basis-point headwind, while product reinvestments and unfavorable mix added pressure, partly offset by productivity savings and tariff benefits.

Management expects about $1.4 billion in after-tax commodity, energy and transportation cost headwinds in fiscal 2027. Higher net interest expense, unfavorable foreign exchange and lower non-operating income are expected to add further pressure, with the combined effects representing a 79-cent-per-share headwind.

PG's Cash Flow Supports Patience

Operating cash flow reached $5.77 billion in the fiscal first quarter, up from $5.41 billion a year earlier. Capital spending totaled $1.37 billion, resulting in free cash flow of about $4.4 billion and free cash flow productivity of 93%.

PG returned $3.9 billion to shareholders during the quarter, including $2.6 billion in dividends and $1.3 billion in share repurchases. For fiscal 2027, management expects free cash flow productivity of 85-90%, more than $10 billion in dividends and about $5 billion in share repurchases.

PG's Scores Support a Cautious Stance

The operating backdrop is improving, but valuation and cost pressure limit the case for becoming more aggressive at current levels. The company’s full-year core earnings outlook calls for growth of 0-3%, reinforcing the gap between improving sales momentum and modest near-term earnings expansion.

PG carries a Zacks Rank #3 (Hold). It also has a VGM Score of D, a Value Score of D, a Growth Score of C and a Momentum Score of D. 

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Style Scores are designed to complement the Zacks Rank, with higher grades generally indicating more favorable characteristics. The current combination supports a patient, selective stance rather than a strong near-term buy signal.

Published in